Developing CILASTATIN for the treatment of GLAUCOMATelara Pharma S.L. is a biotechnology company, spin-off of the Gregorio Marañón Health Research Institute, whose research has revealed the protective effectof the drug CILASTATIN in inflammatory diseases such as Acute Kidney Injury (AKI) and GLAUCOMA. The patents developed for the treatment of AKIhave already been licensed to the pharmaceutical company Arch Biopartners, demonstrating the success of our business strategy. Currently, Telara Pharma hasfilled new patents focused on the application of cilastatin for the treatment of glaucoma. NEUROPROTECTION is currently a huge unmet need and a priority in the field to stop the progression of glaucoma and to prevent blindness.
.png)
